| Background and ObjectiveChronic viral hepatitis B is an infectious disease caused by hepatitis B virus(HBV)infection.Currently,chronic hepatitis B is one of the most common causative agents in chronic liver disease and is the leading cause of cirrhosis and hepatocellular carcinoma(HCC).To study the pathogenesis of chronic hepatitis B,and accordingly the prevention and treatment of CHB has very important clinical significance.CHB is currently thought to be affected by many factors,such as genetic factors,environmental factors and metabolic factors,which genetic factors in the occurrence and development of C HB has a significant role.Mutations of CHB related genes lead to their risk of disease,steatosis and fibrosis.The single nucleotide polymorphism of rs58542926 in transmembrane 6 superfamily member 2(TM6SF2)gene is associated with many diseases such as NAFLD and CHC.At present,there is little research on the association between TM6SF2 rs58542926 gene mutation and C HB steatosis in Han population.The purpose of this study was to evaluate the relationship between TM6SF2 rs58542926 gene polymorphism and non-invasive measurement of liver fat content.MethodThe study was a case-control study in which 288 HBV DNA-positive patients were enrolled in the digestive and internal medicine department of Qingdao Municipal Hospital from February 2017 to October 2017.Among 288 HBV DN A positive patients,CHB patients were male 194 individual and women 94;control group for the same period,Q ingdao Municipal Hospital,physical examination,a total of 106 individuals,44 were male and 62 female.Both groups of subjects underwent transient elastography(TE)measurements to obtain a controlled attenuation parameter(CAP).All subjects were collected clinical indicators(gender,age,nationality)and laboratory related indicators(ALT,AST,GGT,LDL,HBV DNA)to observe the differences between the two groups of general clinical features.The blood samples of the two groups were collected and analyzed by polymerase chain reaction(PCR)as the TM6SF2 genotype.The difference in gene expression between the case group and the control group was observed.To investigate the relationship between TM6SF2 rs58542926 gene polymorphism and CAP in CHB.Data analysis was performed using statistical software SPSS 22.0.ResultCHB group compared with the control group,the general clinical features were statistically significant.There was no significant difference in CAP between the two groups.Three genotypes are sequenced in three groups:in CHB group TT:0.35%,CT:11.46%,CC: 88.19%;in control group TT:0%,C T:9.43%,CC:90.57%?According to the Hardy-Weinberg genetic balance test,the distribution of gene polymorphisms in each group is in line with the Hardy-Weinberg(H-W)balance rule(P>0.05).There was no significant difference in the distribution of T and C alleles between the two groups(P>0.05).Non-conditional logistic regression analysis showed that the risk of C HB patients was(OR =1.285,95%CI=0.611~2.752,P>0.05)of was OR=1.284(95%CI:0.691~2.385,P>0.05)when compared with the T and C alleles.After adjusting for gender and age,the risk of illness in the case group was(OR =1.845,95%CI=0.803~4.238,P>0.05),with no statistical significance.There was no significant difference in CAP between the case group and the control group(P>0.05).In the hepatitis B group,there was a statistically significant difference between LSM,LDL and CAP values in the quantitative assessment of hepatic steatosis by CAP(P<0.05).The difference between TM6SF2 rs58542926 gene polymorphism and CAP in chronic hepatitis B patients was statistically significant(P<0.05).The difference of HBV-DNA level was statistically significant(P<0.05).Conclusions The TM6SF2 rs58542926 gene polymorphism d id not increase the risk of C HB and was associated with CAP values in C HB patients. |
PDF Full Text Request